FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...
The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) that remains inadequately ...
Nearly 8% of Mississippians live with chronic obstructive pulmonary disease (COPD), a long-term, progressive lung disease that causes difficulty breathing. In fact, Mississippi is among the states in ...
More than 10% of Tennesseans live with chronic obstructive pulmonary disease (COPD), a long-term, progressive lung disease that causes difficulty breathing. In fact, Tennessee is one of the top 10 ...